THE BIOFILM COMPANY

KANE BIOTECH

Corporate Presentation

TSX-V: KNE

OTCQB: KNBIF

Q4 - 2024

Forward-Looking Statements

This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, and uncertainties related to the regulatory process and general changes in economic conditions.

Investors should consult the Company's ongoing filings which are available on SEDAR for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update or revise any these forward-looking statements contained herein.

Kane Biotech
is THE Biofilm Company

Leading the advancement of technologies and products that break up biofilms and destroy bacteria

Capitalization Overview

Share Summary

Listing: TSX-V:KNE, OTCQB:KNBIF
Stock Price: $0.12
52 Week Range: $0.05-0.17
Market Cap: $20M
Shares Outstanding: 132.5M
Ownership: Renaud Family & Management 54%; Other 46%

The Biofilm Problem

Biofilms are a glue-like substance excreted by bacteria that…

- protect and allow bacteria to survive and thrive in hostile environments.
- make bacteria up to 1,000 times more resistant to antibiotics and antimicrobials.
- are one of the main contributors to antibiotic resistance. The NIH estimates that 80% of all known human infections are associated with biofilms.

KANE BIOTECH

Biofilm impaired healing is the largest unresolved problem in Wound Care

The Centers for Disease Control and Prevention (CDC) has identified resistant bacteria, which biofilms are a major contributor, as being a serious and urgent clinical and financial burden to health care systems and patients.

$20 MARKET SIZE
BILLION+ USD

Biofilms and link to Dermatology

Recent research has indicated that the persistence of microbial biofilms may be linked to aggravating symptoms associated with common skin conditions including dandruff, seborrheic dermatitis, and acne (which affects 40 to 50 million Americans).

$15 MARKET SIZE
BILLION+ USD

REASONS TO INVEST

Commercializing with a pipeline

1 Proven technology generating revenue today

revyve™ ANTIMICROBIAL WOUND GEL

2 Near-term catalysts

- revyve™ ANTIMICROBIAL WOUND GEL SPRAY — Commercialized H2 2024
- DispersinB® SKIN CLEANSER — Clinical Trial H2 2024
- Acquisition of FBDermatology FLETECH INNOVATION — H2 2024

3 Robust pipeline of new products

- DispersinB® WOUND GEL — Clinical Trial H1 2025
- coactiv+™ STERILE SURGICAL GEL — H2 2025
- revyve™ WOUND CLEANSER — H1 2026

revyve™

ANTIMICROBIAL WOUND GEL

WITH COACTIV+™ TECHNOLOGY

- ☑ US FDA 510(k) cleared
- ☑ Reimbursed by Medicare and Medicaid
- ☑ Growing Global Distribution Network
- ☑ Commercial scale-up manufacturing complete

The hydrogel dressing market in the U.S. was estimated at USD $258 million in 2022

EFFICACY

EASE OF USE

ACCESSIBILITY

Near Term Catalysts

Spray: H2 2024

- Leverages existing FDA Clearance
- New propellant-free, bag-on-valve application system making it ideal for burns or sensitive wounds
- Eliminates any direct physical contact with the burn wound reducing risk of infection and pain
- Patent-pending

Surgical: H1 2025

- Leverages existing pre-clinical testing, accelerating FDA Clearance
- Sterile
- To be used in the hospital operating room to reduce surgical site infections
- Highest margin product

Cleanser: H1 2026

- Leverages existing pre-clinical testing, accelerating FDA Clearance
- To be used in wound care clinics as a wound cleaner and debridement support agent.
- Highest volume product

Growing Distribution Network

1 Signed agreements in UAE and Qatar.
Saudi Arabia, Kuwait, Oman, Bahrain pending.

2 Commercialized through acquisition of
FB Dermatology

KANE BIOTECH

progenacare

SALUDPHARMA Compañía Farmacéutica

2

1

2

2

Product Revenue Profile



1 Proven Technologies

Setting a New Standard in Biofilm Treatment

KANE BIOTECH

coactiv+™

Derived From GRAS Ingredients

Kane Biotech's patented coactiv+™ technology is specifically formulated to destabilize biofilm with demonstrated efficacy and safety through animal oral care clinical trials and two human consumer trials on its DermaKB™ Shampoo.

- Technology used in animal care & human health industries
- Effective against bacterial and fungal biofilms
- Efficacy and safety demonstrated through two pet oral care clinical trials and two human shampoo consumer trials
- Simple regulatory path, combination of GRAS (generally regarded as safe) ingredients

Prolonged activity

revyve™ ANTIMICROBIAL WOUND GEL

DermaKB

DispersinB®

A Naturally Occurring Enzyme

Kane Biotech's patented, antibiofilm DispersinB® technology has demonstrated efficacy, safety, and stability both in vitro and in vivo. DispersinB® is the only enzyme that specifically targets the biofilm framework, destroying the biofilm exopolymeric matrix from the inside.

- Disruptive technology, very fast acting
- Effective against PNAG biofilms (approx. 75% of bacteria)
- Efficacy and safety demonstrated through scientific research papers
- No identified competitors

Fast Acting

3 Robust Pipeline

DispersinB®

THE Missing Link in Wound Care.

- Pursuing PMA Pathway - Allow for DispersinB® to become the first product to receive biofilm related claims and obtain a new reimbursement code for a higher price point

Significantly Accelerated Healing of Wounds Compared to Controls in Pre-Clinical Trials

- Extensive pre-clinical testing conducted. Passed all safety and biocompatibility tests

United-States Department of Defense Funded

- USD $2.7M in non-dilutive funding from the U.S. Department of Defense based on Medical Technology Enterprise Consortium (MTEC) Research Project Award
- In 2022, awarded an additional USD $425k of funding based on positive results from extensive safety and biocompatibility pre-clinical work

Clinical Trial Beginning in H1-2025

- 9-month, 75 patient safety trial

DispersinB® Wound Gel is a clear hydrogel containing a thermo-reversible thickening agent, mild preservatives, and the patented buffered Dispersin B® enzyme.

How Biofilms Lead to Acne

- Acne is a significant problem for millions of people with the global acne treatment market determined at USD $9.36 billion in 2022
- DispersinB destroys *S. epidermidis* PNAG biofilm plug providing access to treat anaerobic *C. acnes*
- Planned 12-week clinical trial is 24 patients with acne vulgaris, half-face treated with DispersinB gel, then entire face treated with Benzoyl Peroxide.

DispersinB®

Biofilm model of acne follicular anaerobiosis



Management

Dr. Robert Huizinga
Executive Chair

Dr. Huizinga joined KANE Biotech in February 2024 and is also currently the principal of Reformation Consulting Services. He was formerly the Executive Vice-President of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and led the clinical development of voclosporin which had first year sales of $100 million USD.

Prior to that, Dr. Huizinga was the Vice President of Clinical Affairs for Isotechnika Inc. (TSV:ISA), and was a clinical investigator at the University of Alberta.

Marc Edwards
President, CEO, Director

Mr. Edwards was appointed as the President and CEO of the Corporation on September 10, 2018. He is the founder and President of VétRx Inc., a Montreal-based technology company specializing in data collection, cleansing, marketing and pharmaceutical compliance for the veterinary industry.

He also co-founded and was vice president of Oxygen Corporate Health from 2003 to 2008 which was later acquired by CGI Inc.

What is it?

- Italian-based biotechnology created by Francesco Bellini (BioChem Pharma, Bellus Health)
- Uses Fluorescent Light Energy (FLE) an exclusive and patented solutions for advanced wound care, dermatology and aesthetics
- Operations in Italy and Australia with approximately $2M in product sales throughout Europe, Australia and New Zealand.
- Three main products:
  - Lumiheal®
    - EU MDR CE Mark for the treatment of chronic wounds Class II de novo device (US FDA) for surgical scar reduction
  - Kleresca®
    - EU CE Mark, stimulates the skin's own repair systems used for skin rejuvenation and the treatment of acne and rosacea
- Lumixa®
  - acts through Photobiomodulation light stimuli activating biological processes and regeneration mechanisms of skin

The agreement to acquire of FB Dermatology was completed by way of binding term sheet on November 12, 2024

Synergies

- Accelerated commercialization of Kane Biotech's revyve™ Antimicrobial Wound Gel in a number of international markets including but not limited to Australia and New Zealand.
- Leveraging FB Dermatology's sales and distribution networks in Europe, Australia and New Zealand to launch Kane's DermaKB™ scalp care product line in those jurisdictions.
- The commercial launch of Lumixa® in the United States and Canada for wound care and dermatological applications along with Kane Biotech's revyve™ product line.
- The US commercial launch of FB Dermatology's LumiHeal® technology for surgical scar reduction along with Kane Biotech's coactiv+™ Antimicrobial Surgical Gel.

The agreement to acquire of FB Dermatology was completed by way of binding term sheet on November 12, 2024

STEM Animal Health – Transaction Details

KANE BIOTECH

100% of STEM Sold to Dechra Veterinary Products for $12.5M USD

- Demonstrates the high value of Kane’s technology portfolio

For Kane's 67% ownership it received:

- $8M USD ($10,900,000 CDN)
- $1M CDN Working Capital
- Product Development Agreement
- Transitionary Manufacturing Agreement
- Future $750K USD One-Time Milestone Payment
- Cash Free/Debt Free Transaction

Dechra

Transaction will ultimately net Kane over $13M CDN

The sale of STEM Animal Health was completed by way of a share purchase agreement between Kane, STEM, Ecuphar NV and Dechra dated April 12, 2024.

Conclusion

1. **Proven technology generating revenue today**
2. **Near-term catalysts and potential M&A**
3. **Robust pipeline of new products**

Q4 2024

- ☑ Financing announcement
- ☑ Potential M&A announcement
- ☑ Announce distribution agreements outside of North America
- ☑ Obtain clearance from Health Canada on revyve™ Antimicrobial Wound Gel
- ❑ Launch revyve™ Antimicrobial Wound Gel Spray
- ❑ Commence DispersinB University of Miami Clinical Trial

H1 2025

- ❑ Closing of FB Dermatology Acquisition
- ❑ Obtain IDE for DispersinB® Wound Gel and commence clinical trial

KANE BIOTECH

Contact Information:

Marc Edwards, Chief Executive Officer
medwards@kanebiotech.com
C: (514) 910-6991

Ray Dupuis, Chief Financial Officer
rdupuis@kanebiotech.com
C: (204) 298-2200

KANEBIOTECH.COM



Kane Biotech Company Timeline: 2023 - 2025